Craig Mello

Type: Person
Name: Craig Mello
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Running Interference

In Guinea, West Africa, February is the dry season; a dusty haze, stirred by the northeasterly harmattan winds, thickens the air. This year, the winds were harbingers of ill omen. That same month, Guineans began falling ill with symptoms ranging from ... [Published The Chemical Institute of Canada - Aug 26 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014

SOURCE RXi Pharmaceuticals CorporationMARLBOROUGH, Mass.Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO"Despite the general market down-turn in sentiment about biotech values, RXi Pharmaceuticals has continued to grow value in line with ... [Published WBAY Green Bay - Aug 14 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

The race against Ebola

Ebola does not spread easily, but when it does—through saliva, blood or contact—the virus is prolific, slipping inside a human cell and replicating itself using the cell’s genetic material, making more than a million versions of itself in 1 millimetre ... [Published Livemint.com - Aug 07 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

RXi Pharmaceuticals: Early-Stage Biotech With A Promising Future

Summary RXi uses a unique version of RNAi technology called sd-rxRNA. RXi has a family tree thatincludes Galena, CytRX, and several RNAi companies. Controversies with Galena/CytRX may be having a negative impact on RXi. RXI-109 shows promise in scarring ... [Published Seeking Alpha - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell

MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted ... [Published Scottrade - Aug 04 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars

/PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that ... [Published OSIX News - Jul 30 2014]
First reported May 06 2014 - Updated May 06 2014 - 1 reports

CRISPR In the Courts

Here's an article from the Independent on the legal battles that are underway about CRISPR technology. On one level, it can be a somewhat ugly story, but it also shows how much of a discovery the technique has been, that people are willing to ... [Published In the Pipeline - May 06 2014]
First reported Apr 24 2014 - Updated Apr 24 2014 - 1 reports

CRISPR Therapeutics grabs $25 mln from Versant Ventures

CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9. PRESS RELEASE BASEL, Switzerland–(BUSINESS ... [Published PE Hub Blog - Apr 24 2014]

More Content

All (9) | News (7) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Running Interference [Published The Chemical Institute of Canada - Aug 26 2014]
RXi Pharmaceuticals Reports Financial Results f... [Published WBAY Green Bay - Aug 14 2014]
RXi Pharmaceuticals Reports Financial Results f... [Published TickerTech.com - Aug 14 2014]
The race against Ebola [Published Livemint.com - Aug 07 2014]
RXi Pharmaceuticals: Early-Stage Biotech With A... [Published Seeking Alpha - Aug 04 2014]
RXi Pharmaceuticals to Ring the NASDAQ Stock Ma... [Published Scottrade - Aug 04 2014]
RXi Pharmaceuticals Expands Clinical Program wi... [Published OSIX News - Jul 30 2014]
CRISPR In the Courts [Published In the Pipeline - May 06 2014]
CRISPR Therapeutics grabs $25 mln from Versant ... [Published PE Hub Blog - Apr 24 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CRISPR In the Courts [Published In the Pipeline - May 06 2014]
Here's an article from the Independent on the legal battles that are underway about CRISPR technology. On one level, it can be a somewhat ugly story, but it also shows how much of a discovery the technique has been, that people are willing to ...
CRISPR Therapeutics grabs $25 mln from Versant ... [Published PE Hub Blog - Apr 24 2014]
CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9. PRESS RELEASE BASEL, Switzerland–(BUSINESS ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.